Coagulation Profile (4)
A focused veterinary coagulation panel covering PT, APTT, TT, and FIB for rapid screening of secondary hemostasis, clotting factor defects, consumptive coagulopathy, liver-related coagulopathy, and anticoagulant rodenticide suspicion.
High-value clinical uses
Useful for unexplained bleeding, pre-surgical risk review, rodenticide suspicion, liver failure workup, DIC screening support, and follow-up of anticoagulant or coagulation-factor disorders.
Core coverage
Extrinsic pathway screening, intrinsic pathway screening, final fibrin formation assessment, and fibrinogen concentration support in one compact profile.
Interpretation focus
This profile evaluates secondary hemostasis. It does not replace platelet count, blood smear review, von Willebrand testing, D-dimer, or viscoelastic testing when those are clinically indicated.
What this panel is for
The Coagulation Profile (4) is designed as a practical screening panel for disorders of fibrin clot formation in veterinary patients. It helps distinguish whether a clotting abnormality is more consistent with an extrinsic pathway problem, an intrinsic pathway problem, a common pathway defect, fibrinogen abnormality, or a broader consumptive/synthetic disorder. It is particularly useful when patients present with spontaneous bleeding, persistent oozing after venipuncture or surgery, suspected anticoagulant rodenticide exposure, liver disease, shock, sepsis, or possible disseminated intravascular coagulation.
Measured parameters (4)
Sample and handling essentials
Specimen
Sodium citrate anticoagulated plasma is the standard specimen for coagulation testing. Platelet-poor citrated plasma is preferred for reliable clotting-time measurement.
Critical fill ratio
The citrate-to-blood ratio must be correct, typically 1:9. Underfilling or overfilling the tube can artifactually prolong clotting times and produce misleading results.
Pre-analytical priority
Use a clean venipuncture, avoid clotting and tissue contamination, separate plasma promptly, and test or freeze according to the analyzer or laboratory protocol.
When to be cautious
Heparin contamination, partially clotted samples, delayed processing, poor tube fill, difficult blood draws, or severe hemolysis can distort results and should trigger recollection when possible.
What each parameter means
PT — Prothrombin Time
PT screens the extrinsic and common pathways. In practical use it is especially helpful for detecting factor VII problems and early vitamin K-dependent factor deficiency or antagonism, including anticoagulant rodenticide exposure. PT often becomes abnormal before APTT in early vitamin K deficiency because factor VII has a short half-life.
APTT — Activated Partial Thromboplastin Time
APTT screens the intrinsic and common pathways. It helps identify deficiencies involving factors such as XII, XI, IX, and VIII, and can support investigation of hemophilia-type disorders, common pathway defects, DIC, liver failure, or heparin effect.
TT — Thrombin Time
TT evaluates the final conversion of fibrinogen to fibrin after thrombin is added. It is particularly sensitive to low or dysfunctional fibrinogen and can also be prolonged by heparin contamination or other inhibitors of fibrin polymerization.
FIB — Fibrinogen
Fibrinogen is both a clotting substrate and an acute-phase protein. Low fibrinogen supports consumption, severe liver synthetic failure, or rare inherited defects. High fibrinogen can occur with inflammation and should be interpreted with the rest of the profile and the clinical picture.
Quick interpretation guide
| Parameter | Main intent of use | When prolonged / increased may suggest | When normal / decreased may mean |
|---|---|---|---|
| PT | Extrinsic + common pathway screen | Factor VII deficiency, early vitamin K antagonism/deficiency, DIC, liver disease, common pathway factor deficiency | Normal PT does not rule out intrinsic pathway disease, platelet disorders, or mild factor deficiencies |
| APTT | Intrinsic + common pathway screen | Hemophilia-type disorders, intrinsic pathway factor deficiency, DIC, liver disease, unfractionated heparin effect, collection artifact | Normal APTT does not rule out extrinsic pathway disease or all bleeding disorders |
| TT | Fibrinogen-to-fibrin conversion | Hypofibrinogenemia, dysfibrinogenemia, heparin contamination/therapy, inhibitors of fibrin polymerization | Normal TT makes a severe final-step fibrinogen problem less likely but not impossible in every method |
| FIB | Clot substrate and inflammatory support marker | Inflammation, acute-phase response, some species-specific inflammatory conditions | Consumption, severe liver synthetic failure, severe bleeding, rare inherited fibrinogen defects |
Use species- and analyzer-specific reference intervals from the exact instrument IFU or your laboratory. Coagulation results are highly method dependent and should not be transferred between platforms without validation.
Pattern-based diagnostic scenarios
1) PT prolonged, APTT normal
This pattern points most strongly toward an extrinsic pathway problem, especially factor VII deficiency or early vitamin K antagonism/deficiency. It can fit early anticoagulant rodenticide toxicosis before broader factor depletion develops.
2) APTT prolonged, PT normal
This pattern supports an intrinsic pathway defect, such as factor XII, XI, IX, or VIII deficiency, and can occur with hemophilia-type disorders. It may also be seen with heparin contamination or poor sample collection.
3) TT prolonged in isolation
This is unusual but can indicate low or abnormal fibrinogen or interference with fibrin polymerization. Heparin contamination should be considered early, especially if sampling involved flushed lines or anticoagulated catheters.
4) PT and APTT both prolonged, TT normal
This supports a defect affecting the common pathway or multiple factor deficiencies involving both extrinsic and intrinsic arms. Major considerations include overt DIC, vitamin K antagonism once multiple factors are depleted, liver disease, or serious sample dilution/handling problems.
5) PT, APTT, and TT all prolonged
This broader abnormality raises concern for severe hypofibrinogenemia, overt DIC, advanced liver synthetic failure, heparin effect, or major pre-analytical error. Evaluate fibrinogen, platelet count, D-dimer/FDP, liver status, and sample integrity immediately.
6) Fibrinogen low with prolonged times
This combination supports consumption or poor synthesis, such as fulminant DIC, severe hepatic failure, or massive bleeding. The lower the fibrinogen, the more likely PT and APTT will also prolong.
7) Fibrinogen high but times near normal
This more often fits an inflammatory acute-phase response than a primary bleeding disorder. It does not by itself mean the patient is safe from coagulation complications.
8) Normal panel but bleeding patient
Consider primary hemostatic disorders such as thrombocytopenia, platelet dysfunction, or von Willebrand disease, as well as local vascular injury or a mild factor deficiency below test sensitivity.
How this panel supports clinical decisions
Bleeding workup
Helps differentiate secondary hemostatic defects from platelet/vessel disorders when used alongside platelet count, blood smear, history, and exam findings such as petechiae versus cavitary or deep-tissue bleeding.
Rodenticide suspicion
Supports screening in cases of possible anticoagulant exposure, especially when PT begins to prolong before APTT becomes abnormal.
Liver disease support
Useful in advanced or synthetic liver dysfunction, where PT/APTT prolongation and low fibrinogen can indicate impaired coagulation factor production.
DIC / critical care support
Provides initial coagulation screening support, but DIC assessment is stronger when combined with platelet count, D-dimer or FDP, antithrombin, fibrinogen trend, and the underlying disease context.
Reference interval note
This page intentionally does not publish numeric reference intervals because coagulation assay ranges are highly species-specific, reagent-specific, and analyzer-specific. For release or labeling, use the exact intervals from the validated panel IFU or from your own laboratory validation on the target platform.
References
Primary product / IFU reference
- Coagulation analyzer IFU. Use the exact platform-specific IFU to confirm specimen type, sample volume, reagent method, clot detection technology, reportable range, and validated reference intervals before publication or clinical deployment.